---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000045"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-06-11T11:16:14+00:00"
generated_at: "2026-06-11T11:20:34.162172+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma exchanges ~69% of 8% Convertible Notes due 2028 for cash and stock

## Summary
- Entered private exchange to retire ~$23M (69%) of 8% Convertible Senior Notes due 2028.
- Exchange consideration: $23M cash plus shares based on 21-day VWAP; ~4.6M shares if price is $6.71.
- After exchange, $10.5M notes remain outstanding; annual interest savings ~$2M.
- Expected close around July 15, 2026; Morgan Stanley acted as placement agent.

## SEC filing metadata
- accession: 0001867096-26-000045
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-06-11T11:16:14+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/0001867096-26-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/xers-20260610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000045
- JSON: https://secwatch.observer/filing/0001867096-26-000045.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000045.txt

## Key facts
- Equity Issuances
  Xeris Biopharma Holdings, Inc. issued common stock to certain holders (the "Noteholders") of its 8.00% Convertible Senior Notes due 2028 for approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company's common stock.
  - Security: common stock
  - Purchaser: certain holders (the "Noteholders") of its 8.00% Convertible Senior Notes due 2028
  - Consideration: approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company's common stock
  source text: On June 10, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders (the “Noteholders”) of its 8.00% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which the Noteholders have agreed to exchange (the “Exchange”) approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company’s common stock (the “Exchange Consideration”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/0001867096-26-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.